Negative / Null Result ReportOpen accessMedicine
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
View details →DOI: 10.1158/1078-0432.ccr-25-0618 Negative / Null Result Report
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
View details →DOI: 10.21203/rs.3.rs-268461/v1 Negative / Null Result ReportMedicine
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
View details →DOI: 10.1007/s10549-021-06292-7 Negative / Null Result ReportMedicine
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
View details →DOI: 10.1177/13524585211032803 Negative / Null Result ReportOpen accessMedicine
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
View details →DOI: 10.3389/fonc.2022.932105 Negative / Null Result ReportOpen accessMedicine
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
View details →DOI: 10.5853/jos.2025.01200 Negative / Null Result ReportOpen accessMedicine
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
View details →DOI: 10.1038/s41392-025-02173-3 Negative / Null Result ReportOpen accessMedicine
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
View details →DOI: 10.1136/jitc-2023-008409 Negative / Null Result ReportOpen accessMedicine
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →DOI: 10.3390/cancers18111802 Negative / Null Result ReportMedicine
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →DOI: 10.1007/s40261-020-00905-7 Negative / Null Result ReportOpen accessMedicine
Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
View details →DOI: 10.1016/j.breast.2023.06.007 Negative / Null Result ReportMedicine
Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer
Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…
View details →DOI: 10.1002/cncr.35151 Negative / Null Result ReportMedicine
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
View details →DOI: 10.1093/rheumatology/kead281 Negative / Null Result ReportOpen accessMedicine
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
View details →DOI: 10.1093/oncolo/oyaf162 Negative / Null Result ReportOpen accessMedicine
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
View details →DOI: 10.3389/fcvm.2025.1578159 Negative / Null Result ReportMedicine
Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
View details →DOI: 10.1016/j.euo.2025.04.026 Negative / Null Result ReportOpen accessMedicine
Choi SW, Jung HA, Cho HJ et al. · 2023 · Cancer medicine
Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. Methods This study was a multicenter,…
View details →DOI: 10.1002/cam4.6213 Negative / Null Result ReportMedicine
Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…
View details →DOI: 10.1111/ajt.15924 Negative / Null Result ReportOpen accessMedicine
Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology
Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…
View details →DOI: 10.1093/neuonc/noaf156 Negative / Null Result ReportMedicine
Çalışkan B · 2025 · International ophthalmology
Purpose To evaluate serum lipid profiles with triglyceride-Glucose (TyG) and TG/HDL-c indices in patients with exudative type age-related macular degeneration. Methods A total of 71 participants were included in the study: 35 with…
View details →DOI: 10.1007/s10792-025-03665-5 Negative / Null Result ReportMedicine
Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology
Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…
View details →DOI: 10.1016/j.ygyno.2023.01.021 Negative / Null Result ReportMedicine
O'Hara MH, Jegede O, Dickson MA et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…
View details →DOI: 10.1158/1078-0432.ccr-24-0036 Negative / Null Result ReportMedicine
Bateman RJ, Li Y, McDade EM et al. · 2025 · The Lancet. Neurology
Background Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The…
View details →DOI: 10.1016/s1474-4422(25)00024-9 Negative / Null Result ReportOpen accessMedicine
Hamamoto H, Suzuki Y, Takano Y et al. · 2022 · BMC surgery
Background This retrospective study aimed to compare long-term oncological outcomes between laparoscopic-assisted colectomy (LAC) with extracorporeal anastomosis (EA) and totally laparoscopic colectomy (TLC) with intracorporeal anastomosis…
View details →DOI: 10.1186/s12893-022-01798-3 Negative / Null Result ReportOpen accessMedicine
Borghaei H, O'Byrne KJ, Paz-Ares L et al. · 2023 · ESMO open
Background In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus…
View details →DOI: 10.1016/j.esmoop.2023.102065 Negative / Null Result ReportOpen accessMedicine
Cacko A, Kozyra-Pydyś E, Gawałko M et al. · 2021 · Cardiology journal
Background Among patients with an implanted cardiac implantable electronic device (CIED), ipsilateral upper extremity vein stenosis or occlusion (VSO) is observed more frequently than in the general population. However, there are no data…
View details →DOI: 10.5603/cj.a2019.0030 Negative / Null Result ReportMedicine
Choueiri TK, Albiges L, Barthélémy P et al. · 2024 · Lancet (London, England)
Background Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing…
View details →DOI: 10.1016/s0140-6736(24)01758-6 Negative / Null Result ReportOpen accessMedicine
Konno Y, Mayama M, Takehara K et al. · 2025 · Journal of gynecologic oncology
Objective This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence. Methods Japanese…
View details →DOI: 10.3802/jgo.2025.36.e57 Negative / Null Result ReportMedicine
Rascol O, Tönges L, deVries T et al. · 2022 · Parkinsonism & related disorders
Background Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core…
View details →DOI: 10.1016/j.parkreldis.2022.01.022 Negative / Null Result ReportMedicine
Takenaka Y, Maeda K, Yamada M et al. · 2026 · Behavioural brain research
Background Motor imagery (MI) improves motor performance, but standardized objective quality evaluation methods are lacking. The relationship between MI quality and actual performance improvements also remains unclear. Purpose We…
View details →DOI: 10.1016/j.bbr.2026.116299 